[1-(4-chlorobenzoyl)-4-fluoro-5-hydroxy-2-methyl-1H-indol-3-yl]acetic acid | 823177-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: [1-(4-chlorobenzoyl)-4-fluoro-5-hydroxy-2-methyl-1H-indol-3-yl]acetic acid
• 英文别名: 2-[1-(4-chlorobenzoyl)-4-fluoro-5-hydroxy-2-methylindol-3-yl]acetic acid
• CAS: 823177-76-0
• 化学式: C₁₈H₁₃ClFNO₄
• 分子量: 361.757
• InChiKey: KJPWRIFRSCIKRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  79.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  [1-(4-chlorobenzoyl)-4-fluoro-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid 在 三溴化硼 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 二氯甲烷 为溶剂， 生成 [1-(4-chlorobenzoyl)-4-fluoro-5-hydroxy-2-methyl-1H-indol-3-yl]acetic acid
  参考文献：
  名称：

  Synthesis of COX-2 and FAAH inhibitors

  摘要：

  描述了制备对COX-2抑制剂有用的吲哚和在这些方法中有用的中间体的方法。

  公开号：

  US20050234244A1

文献信息

• USEFUL INDOLE COMPOUNDS
  申请人：Bartolini Wilmin

  公开号：US20090264653A1

  公开（公告）日：2009-10-22

  Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.

  本文描述了具有FAAH抑制剂活性的吲哚化合物，以及具有DAO抑制剂活性的吲哚及其衍生物。
• Selective Cox-2 Inhibitors
  申请人：Cali M. Brian

  公开号：US20070293542A1

  公开（公告）日：2007-12-20

  The invention features compounds that are inhibitors of COX-2 activity. Certain of the compounds are inhibitors of FAAH activity as well as COX-2 activity. The compounds include a 5-membered or 6-membered substituted or unsubstituted heteroaryl or heterocyclyl ring having one or two heteroatoms selected from the group consisting of O, S, and N that is linked to two substituted or unsubstituted 6-membered aryl or heteroaryl groups that can be the same or different.

  这项发明涉及一种抑制COX-2活性的化合物。其中一些化合物不仅是COX-2活性的抑制剂，还是FAAH活性的抑制剂。这些化合物包括一个带有一个或两个O、S或N杂原子的5元或6元取代或未取代的杂芳基或杂环基环，该环连接两个取代或未取代的6元芳基或杂芳基基团，这两个基团可以相同也可以不同。
• INDOLE COMPOUNDS
  申请人：Talley John Jeffrey

  公开号：US20100197708A1

  公开（公告）日：2010-08-05

  Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

  本文介绍了用于治疗疼痛、炎症和其他疾病的吲哚衍生物。其中某些化合物是苄基衍生物，而其他化合物是苯甲酰基衍生物。这些化合物至少在吲哚的3位被取代。
• 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS
  申请人：FIBROGEN, INC.

  公开号：US20150038528A1

  公开（公告）日：2015-02-05

  The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

  本发明涉及公式（I）的新型化合物及其组合物，能够选择性地抑制PHD1酶活性，而不影响其他同工酶，例如PHD2和/或PHD3酶。本发明还涉及公式（I）的化合物在肌肉退化、结肠炎、炎症性肠病和某些缺血症等疾病中的使用。
• Pharmaceutical combinations and their use in treating gastrointestinal disorders
  申请人：Novartis AG

  公开号：EP1488788A1

  公开（公告）日：2004-12-22

  The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The pharmaceutical combination may be employed for the treatment of altered gastrointestinal motility, sensitivity, secretion or abdominal disorders. The dosage is preferably oral. The preferred first agent is tegaserod.

  本发明涉及一种包括 5-HT4 受体激动剂或拮抗剂或 5-HT3 受体拮抗剂在内的第一药剂与辅助药剂的组合，以及含有该组合的药物组合物和制剂。该药物组合可用于治疗胃肠道蠕动、敏感性、分泌或腹部疾病的改变。用量最好是口服。首选的第一种制剂是替加色罗。